LexDanaLexDanabeta
Inventor

Anastasia Khvorova

Inventor
Boulder, CO, US

Overview

171→
Patents
2001–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 171 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary
C12NMicroorganisms or enzymes31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology19%
A61KPreparations for medical, dental or toiletry purposes12%
C12YEnzymes9%
C07HSugars4%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
C07KPeptides1%
A01KAnimal husbandry0%
G06FElectric digital data processing0%
PatentTitleYear
11,118,178Reduced size self-delivering RNAI compounds202110,876,119Reduced size self-delivering RNAI compounds202010,844,377Two-tailed self-delivering siRNA202010,815,485RNA interference in skin indications202010,799,591Branched oligonucleotides202010,774,327Oligonucleotide compounds for targeting huntingtin mRNA202010,774,330Reduced size self-delivering RNAI compounds202010,765,695Methods and compositions for selecting siRNA of improved functionality202010,696,968Methods and compositions for selecting siRNA of improved functionality202010,662,430RNA interference in ocular indications202010,633,654Modified RNAi polynucleotides and uses thereof202010,633,653Bioactive conjugates for oligonucleotide delivery202010,519,451Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders201910,513,710Exosomal loading using hydrophobically modified oligonucleotides201910,479,992RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality201910,478,503Branched oligonucleotides201910,435,688Oligonucleotide compounds for targeting huntingtin mRNA201910,421,970Methods and compositions for selecting siRNA of improved functionality201910,240,149Reduced size self-delivering RNAi compounds201910,233,449Methods and compositions for selecting siRNA of improved functionality201910,184,124RNA interference in ocular indications201910,167,471Inhibition of PCSK9 through RNAI201910,138,485Neutral nanotransporters201810,131,904Modified RNAi polynucleotides and uses thereof201810,041,073Reduced size self-delivering RNAi compounds201810,011,836Methods and compositions for selecting siRNA of improved functionality20189,963,702RNA interference in dermal and fibrotic indications20189,938,530RNA interference in skin indications20189,879,266'Methods and compositions for selecting siRNA of improved functionality'20189,862,952'Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders'20189,839,649'Methods and compositions for selecting siRNA of improved functionality'20179,809,817'Oligonucleotide compounds for targeting huntingtin mRNA'20179,777,270'Methods and compositions for selecting siRNA of improved functionality'20179,771,586'RNAi targeting ZNF205'20179,745,574'RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality'20179,719,092'RNAi targeting CNTD2'20179,719,094'RNAi targeting SEC61G'20179,493,774'Inhibition of PCSK9 through RNAi'20169,353,368'Micro-RNA scaffolds and non-naturally occurring micro-RNAs'20169,340,786'RNA interference in dermal and fibrotic indications'20169,334,495'Minor groove binder (MGB)-oligonucleotide miRNA antagonists'20169,303,259'RNA interference in skin indications'20169,284,554'Micro-RNA scaffolds and non-naturally occurring micro-RNAs'20169,228,186'Methods and compositions for selecting siRNA of improved functionality'20169,175,289'Reduced size self-delivering RNAi compounds'20159,095,504'RNA interference in ocular indications'20159,080,171'Reduced size self-delivering RNAi compounds'20159,074,211'Inhibition of MAP4K4 through RNAI'20158,980,855'Minor groove binder (MGB)-oligonucleotide miRNA antagonists'20158,937,172'siRNA targeting catenin, beta-1 (CTNNB1)'20158,907,077'siRNA targeting TIE-2'20148,841,267'Micro-RNA scaffolds, non-naturally occurring micro-RNAs, and methods for optimizing non-naturally occurring micro-RNAs'20148,809,514'Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference'20148,796,443'Reduced size self-delivering RNAi compounds'20148,664,189'RNA interference in skin indications'20148,658,784'siRNA targeting amyloid beta (A4) precursor protein (APP)'20148,658,785'siRNA targeting tie-2'20148,633,306'SiRNA targeting histamine receptor H1'20148,575,329'siRNA targeting kinase insert domain receptor (KDR)'20138,501,706'Duplex oligonucleotide complexes and methods for gene silencing by RNA interference'20138,461,326'SiRNA targeting connective tissue growth factor (CTGF)'20138,445,667'SiRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)'20138,445,668'SiRNA targeting apolipoprotein (APOB)'20138,426,579'SiRNA targeting myeloid differentiation primary response gene (88) (MYD88)'20138,415,466'Duplex oligonucleotides with enhanced functionality in gene regulation'20138,399,654'siRNA targeting catenin, Beat-1 (CTNNB1)'20138,367,318'Screening of micro-RNA cluster inhibitor pools'20138,314,229'siRNA targeting tie-2'20128,304,528'SiRNA targeting fructose-1, 6-bisphosphatase 1 (FBP1)'20128,293,887'SiRNA targeting beta secretase (BACE)'20128,268,985'siRNA targeting amyloid beta (A4) precursor protein (APP)'20128,252,755'Duplex oligonucleotide complexes and methods for gene silencing by RNA interference'20128,247,169'SiRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2)'20128,236,942'SiRNA targeting glucagon receptor (GCGR)'20128,232,385'siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)'20128,232,386'SiRNA targeting apolipoprotein B (APOB)'20128,222,395'siRNA targeting kinase insert domain receptor (KDR)'20128,222,396'SiRNA targeting proto-oncogene MET'20128,217,162'siRNA targeting interleukin-1 receptor-associated kinase 4(IRAK4)'20128,198,427'SiRNA targeting catenin, beta-1 (CTNNB1)'20128,188,060'Duplex oligonucleotides with enhanced functionality in gene regulation'20128,138,329'siRNA targeting connective tissue growth factor (CTGF)'20128,093,370'siRNA targeting spleen tyrosine kinase'20128,090,542'Functional and hyperfunctional siRNA'20128,071,754'siRNA targeting apolipoprotein B (APOB)'20118,067,576'siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase)'20118,039,610'siRNA targeting superoxide dismutase 1 (SOD1)'20118,030,476'siRNA targeting gremlin'20118,030,474'siRNA targeting cyclin-dependent kinase 4 (CDK4)'20118,022,198'siRNA targeting histamine receptor H1'20118,022,199'SiRNA targeting myeloid differentiation primary response gene (88) (MYD88)'20118,013,145'SiRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)'20118,008,474'siRNA targeting KRAS'20118,000,902'Methods and compositions for selecting siRNA of improved functionality'20117,999,097'siRNA targeting beta secretase (BACE)'20117,985,854'siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)'20117,977,471'siRNA targeting TNFα'20117,951,935'siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)'20117,935,813'siRNA target hypoxia-inducible factor 1'20117,935,811'Apparatus and system having dry gene silencing compositions'20117,923,206'Method of determining a cellular response to a biological agent'20117,923,207'Apparatus and system having dry gene silencing pools'20117,897,754'SiRNA targeting ras-related nuclear protein RAN'20117,893,247'siRNA targeting spleen tyrosine kinase'20117,855,186'siRNA targeting TIE-2'20107,834,170'Functional and hyperfunctional siRNA'20107,833,989'siRNA targeting connective tissue growth factor (CTGF)'20107,834,171'Modified polynucleotides for reducing off-target effects in RNA interference'20107,829,696'siRNA targeting amyloid beta (A4) precursor protein (APP)'20107,820,809'Functional and hyperfunctional siRNA directed against Bcl-2'20107,816,512'siRNA targeting proto-oncogene MET'20107,807,819'siRNA targeting survivin'20107,807,820'siRNA targeting beta secretase (BACE)'20107,803,933'siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)'20107,795,420'Functional and hyperfunctional siRNA directed against Bcl-2'20107,795,421'siRNA targeting apolipoprotein B (APOB)'20107,781,575'siRNA targeting tumor protein 53 (p53)'20107,745,612'siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4)'20107,745,610'siRNA targeting cyclin dependent kinase 11 (CDK11)'20107,745,611'siRNA targeting KRAS'20107,741,470'siRNA targeting gremlin'20107,737,267'siRNA targeting hypoxia-inducible factor 1'20107,709,629'siRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2)'20107,696,344'siRNA targeting complement factor B'20107,691,998'siRNA targeting nucleoporin 62kDa (Nup62)'20107,691,997'Functional and hyperfunctional siRNA'20107,678,896'siRNA targeting serine/threonine kinase 12 (STK12 or aurora B kinase)'20107,674,896'siRNA targeting BCL2L1'20107,666,853'siRNA targeting connective tissue growth factor (CTGF)'20107,662,950'siRNA targeting myeloid differentiation primary response gene (88) (MYD88)'20107,655,789'siRNA targeting transient receptor potential cation channel, subfamily V, member 1 (TRPV1)'20107,655,788'siRNA targeting DNA-damage-inducible transcript 4 (DDIT4)'20107,645,870'siRNA targeting proteasome 26S subunit, non-ATPase, 10 (Gankyrin or PSMD10)'20107,645,869'siRNA targeting spleen tyrosine kinase'20107,642,349'siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)'20107,638,622'SiRNA targeting intercellular adhesion molecule 1 (ICAM1)'20097,638,621'siRNA targeting insulin-like growth factor 1 receptor (IGF-1R)'20097,635,770'siRNA targeting protein kinase N-3 (PKN-3)'20097,635,771'siRNA targeting amyloid beta (A4) precursor protein (APP)'20097,632,939'siRNA targeting proto-oncogene MET'20097,632,938'siRNA targeting superoxide dismutase 1 (SOD1)'20097,619,081'siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)'20097,615,541'siRNA targeting TIE-2'20097,612,196'siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)'20097,608,706'siRNA targeting ras-related nuclear protein'20097,608,707'siRNA targeting survivin'20097,605,252'siRNA targeting kinase insert domain receptor (KDR)'20097,605,250'siRNA targeting cAMP-specific phosphodiesterase 4D'20097,598,369'siRNA targeting histamine receptor H1'20097,598,370'siRNA targeting polo-like kinase-1 (PLK-1)'20097,595,388'siRNA targeting EPH receptor A3 (EPHA3)'20097,595,387'Modified polynucleotides for reducing off-target effects in RNA interference'20097,595,389'siRNA targeting casitas B cell lymphoma-B (CBL-B)'20097,592,444'siRNA targeting myeloid cell leukemia sequence 1'20097,592,442'siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)'20097,592,443'siRNA targeting interleukin-1 receptor-associated kinase 4 (IRAK4)'20097,589,191'siRNA targeting hypoxia-inducible factor 1'20097,582,747'siRNA targeting inner centromere protein antigens (INCENP)'20097,582,746'siRNA targeting complement component 3 (C3)'20097,579,458'siRNA targeting synuclein, alpha (SNCA-1)'20097,579,457'siRNA targeting carbonic anhydrase II'20097,576,197'SiRNA targeting KRAS'20097,576,196'siRNA targeting transducin (beta)-like 3 (TBL3)'20097,569,684'siRNA targeting gremlin'20097,550,572'siRNA targeting cell division cycle 20 homolog (CDC20)'20097,541,453'siRNA targeting aquaporin 4'20097,521,191'siRNA targeting connexin 43'20097,514,550'siRNA targeting myeloid cell leukemia sequence 1'20097,511,132'Functional and hyperfunctional siRNA directed against Bcl-2'20097,507,811'siRNA targeting KRAS'20096,225,063'RNA channels in biological membranes'2001

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2001–2015Based in Boulder, CO, US· patent location history
2009–2013Patents assigned to DHARMACON INC (111)· patent assignee history
2011–2018Patents assigned to KHVOROVA ANASTASIA (47)· patent assignee history
2011–2014Patents assigned to LEAKE DEVIN (32)· patent assignee history
2011–2014Patents assigned to MARSHALL WILLIAM (26)· patent assignee history
2011–2014Patents assigned to REYNOLDS ANGELA (26)· patent assignee history
2012–2020Based in Northborough, MA, US· patent location history
2014–2021Based in Westborough, MA, US· patent location history
2018–2020Based in Northborugh, MA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
DHARMACON INC1112009–2013
KHVOROVA ANASTASIAself472011–2018
LEAKE DEVIN322011–2014
MARSHALL WILLIAM262011–2014
REYNOLDS ANGELA262011–2014
Locations
LocationPatentsSpan
Boulder, CO, US1102001–2015
Westborough, Massachusetts, US372014–2021
Northborough, Massachusetts, US222012–2020
Northborugh, Massachusetts, US22018–2020